- Home
- Publications
- Publication Search
- Publication Details
Title
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Authors
Keywords
Type 2 diabetes mellitus, SGLT-2 receptor inhibitors, Empagliflozin, Heart failure, Cardiovascular diseases, Cardiac magnetic resonance
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 32, Issue 2, Pages 213-222
Publisher
Springer Nature
Online
2018-04-20
DOI
10.1007/s10557-018-6786-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Management of Type 2 Diabetes in 2017
- (2017) Jane E. B. Reusch et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Novel Diabetes Drugs and the Cardiovascular Specialist
- (2017) Naveed Sattar et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- (2017) Gian Paolo Fadini et al. Lancet Diabetes & Endocrinology
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/ReperfusionCLINICAL PERSPECTIVE
- (2016) Carlos G. Santos-Gallego et al. CIRCULATION
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
- (2016) Robert J. Smith et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- 8. Pharmacologic Approaches to Glycemic Treatment
- (2016) DIABETES CARE
- Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK
- (2016) S. C. Bain et al. DIABETES OBESITY & METABOLISM
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
- (2016) Abd A. Tahrani et al. Nature Reviews Endocrinology
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica
- (2016) Belén Dalama et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
- (2016) Joel Zonszein et al. Diabetes Therapy
- Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
- (2016) Joel Zonszein et al. Diabetes Therapy
- HDL: Quality or quantity?
- (2015) Carlos G. Santos-Gallego ATHEROSCLEROSIS
- SGLT2 Inhibitors: The Latest “New Kids on the Block”!
- (2015) William T. Cefalu et al. DIABETES CARE
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- HDL Dysfunction
- (2015) Juan J. Badimon et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants
- (2014) Shiying Wu et al. Cardiovascular Therapeutics
- Pathophysiology of Acute Coronary Syndrome
- (2014) Carlos G. Santos-Gallego et al. Current Atherosclerosis Reports
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Beginning to Understand High-Density Lipoproteins
- (2014) Carlos G. Santos-Gallego et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of HDL in Those with Diabetes
- (2014) Carlos G. Santos-Gallego et al. Current Cardiology Reports
- Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
- (2013) R. A. DeFronzo et al. DIABETES CARE
- Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis
- (2013) D. Wu et al. DIABETES OBESITY & METABOLISM
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin: an old but still the best treatment for type 2 diabetes
- (2013) Lilian Beatriz Aguayo Rojas et al. Diabetology & Metabolic Syndrome
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- (2012) Ele Ferrannini et al. Nature Reviews Endocrinology
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Experimental Models for the Investigation of High-Density Lipoprotein–Mediated Cholesterol Efflux
- (2011) Carlos G. Santos-Gallego et al. Current Atherosclerosis Reports
- Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?
- (2011) Juan José Badimón et al. REVISTA ESPANOLA DE CARDIOLOGIA
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started